CHRS · XBRL financial data

Coherus Oncology financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CHRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	38	58	70	159	118	14
Research and development	143	363	199	109	93	109
Selling, general and administrative	139	170	198	192	168	101
Operating income (loss)	156	(264)	(257)	(203)	(112)	(181)
Interest income	1	1	2	3	5	7
Interest expense	21	23	32	41	27	9
Other income (expense)	1	(0)	4	5	3	7
Income tax expense (benefit)	3	0	0	(0)	0	0
Net income (loss)	132	(287)	(292)	(238)	29	168
Earnings per share, basic USD per share	1.85	(3.81)	(3.76)	(2.53)	0.25	1.43
Earnings per share, diluted USD per share	1.62	(3.81)	(3.76)	(2.53)	0.25	1.43
Weighted average shares, basic millions of shares	71	75	78	94	115	117
Weighted average shares, diluted millions of shares	83	75	78	94	115	117

Fiscal years (CHRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	541	417	64	103	126	89
Marketable securities	—	—	128	15	—	83
Inventory	44	38	39	63	70	3
Prepaid and other current assets	6	11	23	11	12	6
Total current assets	767	602	381	476	342	207
Property and equipment, net	10	8	9	5	3	1
Right-of-use asset	10	8	6	6	5	3
Goodwill	1	1	1	1	—	—
Total assets	842	679	481	630	449	258
Accounts payable	15	16	12	35	28	10
Accrued liabilities	23	48	50	105	60	20
Total current liabilities	146	165	139	332	283	140
Lease liability, non-current	9	7	4	5	3	1
Total liabilities	561	582	618	823	581	197
Accumulated deficit	(763)	(1,050)	(1,342)	(1,580)	(1,551)	(1,383)
Total stockholders' equity	281	98	(137)	(193)	(132)	61
Total liabilities and equity	842	679	481	630	449	258
Common shares outstanding (cover page) millions of shares	73	77	80	113	116	150

Fiscal years (CHRS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	132	(287)	(292)	(238)	29	168
Stock-based compensation	38	51	51	43	28	17
Depreciation and amortization	—	4	4	3	2	1
Net cash from operating activities	154	(37)	(241)	(175)	(20)	(139)
Purchases of property and equipment	7	1	2	0	—	—
Net cash from investing activities	(14)	(138)	(167)	145	230	375
Proceeds from issuing common stock	—	41	—	—	1	—
Net cash from financing activities	224	52	54	70	(187)	(274)
Net change in cash	364	(124)	(354)	39	23	(37)

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.